Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

"Starbucks' current offer is insufficient to finalize a deal," the workers union said. Starbucks said in a statement that the ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations.